Clinical timelines destroy marketing plans when trials extend 18+ months. Physician adoption requires evidence most marketing teams can't provide. We fix regulatory navigation and evidence-based adoption for life sciences companies.
The Problem
Clinical trial timelines create unpredictable product launch windows
Your marketing team can't plan campaigns when a Phase II readout slips 12+ months past the original projection. FDA approval timing drives everything from investor updates to when you start hiring a commercial team. Traditional marketing planning assumes a fixed launch date; biotech gives you a moving one, so budgets get built around a quarter that shifts twice before it's real.
FDA promotional restrictions limit marketing claims and pre-approval activities
You can't promote an investigational product or make efficacy claims during clinical development, and FDA guidance on promotional materials means legal review sits in front of every campaign. Work that takes two weeks at a normal B2B company takes six to eight when Medical, Legal, and Regulatory all need sign-off. Marketing ends up doing compliance triage instead of building demand, and leadership sees a function that looks slow with nothing to show before approval.
Physician adoption requires clinical evidence and peer validation
Physicians don't respond to demand-gen tactics. They respond to peer-reviewed data, KOL endorsement, and conference presence, which means a marketing team built around lead scoring and email sequences has no lever to pull when the buying committee is a hospital P&T committee reading a published trial. Scientific credibility has to come from people who can talk to clinicians as peers, not generalists translating a deck.
How We Help
We embed fractional CXOs who understand FDA promotional guidelines, clinical evidence requirements, and physician adoption psychology into your team. They build marketing strategies that work within regulatory constraints while positioning for a compliant commercial launch whenever approval lands.
Our biotech CXOs have navigated FDA promotional review, structured physician evidence programs, and kept commercial readiness moving through unpredictable clinical timelines. We know how to build compliant pre-launch awareness, design evidence-based physician adoption programs, and keep the growth strategy engine running when the launch date is a moving target.
You get senior life sciences marketing leadership without hiring a full-time executive that costs $400K+ and takes 6+ months to recruit in a field where qualified candidates are scarce. We start with an FDA compliance audit, a clinical-milestone marketing calendar built around your actual trial data, and a physician evidence strategy – not a generic marketing audit that ignores the regulatory constraints you operate under.
Within 90 days you have FDA-compliant marketing processes, a plan tied to real trial milestones instead of a fiscal calendar, and a physician adoption framework ready to activate the day approval comes through.
What makes this different: it's an embedded fractional CXO, not an outside consultant handing you a deck. We're accountable for the number, not just the recommendation, and we work in 90-day sprints with clear phase gates so you see movement at each stage, not just at the end.
We build measurement into the engagement from day one – baseline metrics before we touch anything, monthly reporting on what's actually moving, and no vanity numbers standing in for enrollment or adoption data. In a sector where the sales cycle can run five to ten years pre-revenue, tracking the right leading indicators is the difference between knowing the plan is working and guessing.
What we deliver
- FDA promotional compliance frameworks – marketing materials built to clear Medical/Legal/Regulatory review without stalling out
- Clinical timeline marketing alignment – a campaign calendar tied to actual trial milestones, not a fiscal quarter
- Physician evidence adoption programs – KOL and peer-validation strategies built for how clinicians actually decide
- Pre-launch awareness strategies – compliant activity that builds market presence before an approval date exists
- Commercial readiness optimization – a launch-ready plan that activates the moment FDA approval lands
In biotech, the marketing plan isn't broken by strategy – it's broken by a launch date that moves. The fix is building around the clinical milestone, not the fiscal quarter.
Our Methodology
Our methodology runs a 90-day sprint built for immediate impact and systems that hold up through unpredictable trial timelines. In the first 30 days, we embed with your leadership team to audit existing marketing infrastructure, review performance and enrollment data, identify quick wins within FDA constraints, and map the physician and payer landscape specific to your indication. We interview key stakeholders, review your analytics stack, and map the journey from first physician touch to prescribing decision.
Days 30-60 focus on strategy development and early execution. We build a roadmap prioritized against your clinical timeline, restructure team roles where needed, and start implementing the highest-impact changes. This phase includes measurement frameworks tied to real milestones – enrollment pace, compliance turnaround time, physician engagement – not vanity numbers borrowed from a different industry.
Days 60-90 shift to full execution. Compliance processes are running, the team is aligned, and we optimize against real data as the trial progresses. By the end of the sprint, you have a functioning growth engine with clear ownership and a physician adoption framework ready to activate the moment FDA approval lands – something that works whether we stay on or not.
How We Work
In the first 30 days, we run a full marketing and growth audit specific to your regulatory stage: reviewing your analytics stack, interviewing key stakeholders, mapping the physician and payer journey, and identifying the three to five highest-impact opportunities within FDA constraints. We set baseline metrics so progress gets measured against real targets, not vanity numbers.
During days 30-60, we move into strategy development and early execution. We build a prioritized roadmap tied to your clinical timeline, restructure team roles where needed, and start implementing the quick wins identified in the audit. Weekly check-ins keep the team aligned and leadership informed as trial data comes in.
Days 60-90 are full execution mode. Compliance processes are running, the team knows its roles, and we're optimizing based on real performance and enrollment data. We provide monthly strategy presentations to leadership covering what's working, what's not, and what we're changing as the clinical picture evolves.
Most engagements run 3-6 months initially. We work 15-25 hours per week embedded with your team – attending leadership meetings, managing agency and Medical/Legal/Regulatory relationships, and making resource allocation decisions. The goal is systems that outlast the engagement, including a physician adoption framework that activates whenever approval clears.
- FDA compliance optimization
- Clinical timeline alignment
- Physician adoption acceleration
- Commercial launch readiness
If your biotech & life sciences company needs fractional cxo leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does a fractional CMO cost for biotech companies?
Fractional biotech CMOs typically run $22K-$38K monthly depending on clinical stage and FDA complexity. Compare that to $450K+ for a full-time life sciences marketing executive who understands regulatory compliance and physician adoption, plus a 6+ month search in a specialized talent pool. Cost scales with how many products are in active trials and how much Medical/Legal/Regulatory review is required.
Do you handle FDA compliance for biotech marketing?
Yes. We understand FDA promotional guidelines, clinical-stage restrictions, and how to build marketing that works within regulatory constraints for both investigational and approved products. Materials are built to clear Medical/Legal/Regulatory review the first time, not bounce back for rewrites.
Can you help with physician adoption for life sciences products?
Yes. We design evidence-based adoption programs, clinical validation strategies, and peer-influence systems built around how physicians actually make prescribing and formulary decisions. That means KOL engagement and peer-reviewed data, not lead-scoring tactics borrowed from B2B SaaS.
How long before we see results from a fractional CXO?
Initial diagnostic insights and quick wins typically surface within the first 30 days. Structural improvements – compliance processes, measurement frameworks, a clinical-milestone campaign calendar – show up by day 60-90. Compounding effects from systematic changes, including physician adoption traction, become clear at the 3-6 month mark.
How does the fractional model work day-to-day?
We work 15-25 hours per week embedded with your team. That includes attending leadership meetings, managing agency and regulatory-review relationships, making resource allocation decisions, and building the systems above. Weekly check-ins keep execution aligned; monthly strategy presentations give leadership visibility into progress against the clinical timeline.
What makes a fractional CXO different from a marketing consultant?
Consultants hand you frameworks and recommendations. A fractional CXO owns the number and is embedded in your organization, accountable for the plan working inside FDA constraints, not just for the strategy on paper. We execute alongside your team through the full pre-launch and launch cycle instead of delivering a deck and moving to the next client.
